Novasep Launches innovative BioSC Sequential Multi-Column Chromatography for the capture and purification of Biopharmaceuticals
01 October 2007
Introducing Novasep Process BioSC sequential multi-column chromatography: With increasing expression levels of mAbs and recombinant proteins, the Biopharmaceutical Industry has turned its attention to the next process bottleneck: downstream chromatographic purification. BioSC will be a powerful tool in helping the industry meet the major challenges of improving productivity and quality while drastically reducing the cost of downstream processing of biopharmaceuticals such as recombinant proteins, monoclonal antibodies, blood fractions, recombinant vaccines, etc.
Coupling its experience in continuous chromatography and process development, Novasep Process has developed this SMCC technology to:
- Develop new state-of-the-art chromatography processes, which reduce consumption of expensive stationary phase media and buffer solutions while minimizing manufacturing infrastructure
- Implement continuous integrated downstream processing including multiple chromatography, concentration and UF/DF steps thereby balancing the productivity of both the upstream and downstream processes
The uniqueness of the BioSC - SMCC technology lies in its management of 'fluid in' and 'fluid out' and its ability to asynchronously and flexibly schedule each of the multiple columns.
For over 15 years, Novasep Process' commitment to innovation has made it the leader in process purification. With the introduction of BioSC, Novasep Process is addressing three key challenges critical to effective downstream processing:
- Improving productivity
- Cutting purification costs
- Supporting PAT initiatives
In economic analyses, BioSC has demonstrated that it has the power to cut biopharmaceutical downstream processing costs in half by:
- More efficient usage of expensive stationary phase
- Significant reduction by 2-4 fold in CIP and buffer usage
- Downsizing of downstream processing systems and utilities
- Significantly faster processing
- Reduced labor costs through automated process control and analytical analysis
- Enabling continuous downstream processing
- Improving yield and purity for biopharmaceuticals
- Significant improvement of 2-3 fold in productivity g/L of stationary phase
Novasep Process provides enabling products and contract services for biopharmaceutical purification processes from lab to industrial scale; including preparative chromatography systems (LPLC,MPLC, HPLC), ultra and microfiltration membrane and systems to purify your mAbs, r-proteins, vaccines, etc
Novasep Process specializes in developing your purification solutions for the Pharmaceutical, Biopharmaceutical and Industrial Biotech markets. The company offers a full range of services from process development and optimisation to multi-ton scale custom purification.
